825 related articles for article (PubMed ID: 31279808)
1. Dermatomyositis: Clinical features and pathogenesis.
DeWane ME; Waldman R; Lu J
J Am Acad Dermatol; 2020 Feb; 82(2):267-281. PubMed ID: 31279808
[TBL] [Abstract][Full Text] [Related]
2. Dermatomyositis: Diagnosis and treatment.
Waldman R; DeWane ME; Lu J
J Am Acad Dermatol; 2020 Feb; 82(2):283-296. PubMed ID: 31279813
[TBL] [Abstract][Full Text] [Related]
3. Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort.
Bodoki L; Nagy-Vincze M; Griger Z; Betteridge Z; Szöllősi L; Dankó K
Autoimmun Rev; 2014 Dec; 13(12):1211-9. PubMed ID: 25182203
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in dermatomyositis-specific autoantibodies.
Fujimoto M; Watanabe R; Ishitsuka Y; Okiyama N
Curr Opin Rheumatol; 2016 Nov; 28(6):636-44. PubMed ID: 27533321
[TBL] [Abstract][Full Text] [Related]
5. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies.
Gerami P; Schope JM; McDonald L; Walling HW; Sontheimer RD
J Am Acad Dermatol; 2006 Apr; 54(4):597-613. PubMed ID: 16546580
[TBL] [Abstract][Full Text] [Related]
6. [Myositis-specific autoantibodies].
Fujimoto M
Brain Nerve; 2013 Apr; 65(4):449-60. PubMed ID: 23568993
[TBL] [Abstract][Full Text] [Related]
7. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis.
Hoshino K; Muro Y; Sugiura K; Tomita Y; Nakashima R; Mimori T
Rheumatology (Oxford); 2010 Sep; 49(9):1726-33. PubMed ID: 20501546
[TBL] [Abstract][Full Text] [Related]
8. [Comparison of clinical and immunological features between clinically amyopathic dermatomyositis and typical dermatomyositis].
Gan YZ; Li YH; Zhang LH; Ma L; He WW; Jin YB; An Y; Li ZG; Ye H
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Dec; 52(6):1001-1008. PubMed ID: 33331305
[TBL] [Abstract][Full Text] [Related]
9. The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies.
Li S; Ge Y; Yang H; Wang T; Zheng X; Peng Q; Lu X; Wang G
Clin Rheumatol; 2019 Aug; 38(8):2171-2179. PubMed ID: 30863950
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory Myopathies with Cutaneous Involvement: from Diagnosis to Therapy.
Dourmishev LA
Folia Med (Plovdiv); 2017 Mar; 59(1):7-13. PubMed ID: 28384112
[TBL] [Abstract][Full Text] [Related]
11. Specific autoantibodies in dermatomyositis: a helpful tool to classify different clinical subsets.
Merlo G; Clapasson A; Cozzani E; Sanna L; Pesce G; Bagnasco M; Burlando M; Parodi A
Arch Dermatol Res; 2017 Mar; 309(2):87-95. PubMed ID: 27928683
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of serum levels of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositis.
Ikeda N; Yamaguchi Y; Kanaoka M; Ototake Y; Akita A; Watanabe T; Aihara M
J Dermatol; 2020 May; 47(5):490-496. PubMed ID: 32103537
[TBL] [Abstract][Full Text] [Related]
13. [Dermatomyositis: new antibody, new classification].
Bolko L; Gitiaux C; Allenbach Y
Med Sci (Paris); 2019 Nov; 35 Hors série n° 2():18-23. PubMed ID: 31859626
[TBL] [Abstract][Full Text] [Related]
14. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients.
Betteridge Z; Tansley S; Shaddick G; Chinoy H; Cooper RG; New RP; Lilleker JB; Vencovsky J; Chazarain L; Danko K; Nagy-Vincze M; Bodoki L; Dastmalchi M; Ekholm L; Lundberg IE; McHugh N;
J Autoimmun; 2019 Jul; 101():48-55. PubMed ID: 30992170
[TBL] [Abstract][Full Text] [Related]
15. Autoantibodies in polymyositis and dermatomyositis.
Ghirardello A; Bassi N; Palma L; Borella E; Domeneghetti M; Punzi L; Doria A
Curr Rheumatol Rep; 2013 Jun; 15(6):335. PubMed ID: 23591825
[TBL] [Abstract][Full Text] [Related]
16. Clinical subsets of juvenile dermatomyositis classified by myositis-specific autoantibodies: Experience at a single center in Japan.
Iwata N; Nakaseko H; Kohagura T; Yasuoka R; Abe N; Kawabe S; Sugiura S; Muro Y
Mod Rheumatol; 2019 Sep; 29(5):802-807. PubMed ID: 30092736
[No Abstract] [Full Text] [Related]
17. Myositis-specific autoantibodies in dermatomyositis/polymyositis with interstitial lung disease.
Li L; Wang H; Wang Q; Wu C; Liu C; Zhang Y; Cheng L; Zeng X; Zhang F; Li Y
J Neurol Sci; 2019 Feb; 397():123-128. PubMed ID: 30616054
[TBL] [Abstract][Full Text] [Related]
18. Clinical manifestations of skin, lung and muscle diseases in dermatomyositis positive for anti-aminoacyl tRNA synthetase antibodies.
Fukamatsu H; Hirai Y; Miyake T; Kaji T; Morizane S; Yokoyama E; Hamada T; Oono T; Koyama Y; Norikane S; Iwatsuki K
J Dermatol; 2019 Oct; 46(10):886-897. PubMed ID: 31418479
[TBL] [Abstract][Full Text] [Related]
19. [Dermatomyositis and acute interstitial lung disease associated with MDA-5 antibodies: an atypical case].
Girard C; Vincent T; Bessis D
Ann Dermatol Venereol; 2013 Oct; 140(10):628-34. PubMed ID: 24090894
[TBL] [Abstract][Full Text] [Related]
20. [New autoantibodies in dermatomyositis].
Bielsa I
Actas Dermosifiliogr; 2009 Apr; 100(3):182-9. PubMed ID: 19457303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]